Amarin Corporation PLC (AMRN) versus Its Competitors Head-To-Head Review
Amarin Corporation PLC (NASDAQ: AMRN) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Amarin Corporation PLC to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, risk, profitability and dividends.
This is a summary of recent recommendations for Amarin Corporation PLC and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Amarin Corporation PLC||0||0||3||0||3.00|
|Amarin Corporation PLC Competitors||808||3168||11489||230||2.71|
Insider and Institutional Ownership
39.1% of Amarin Corporation PLC shares are held by institutional investors. Comparatively, 49.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.7% of Amarin Corporation PLC shares are held by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Amarin Corporation PLC has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Amarin Corporation PLC’s peers have a beta of 6.30, suggesting that their average share price is 530% more volatile than the S&P 500.
Valuation & Earnings
This table compares Amarin Corporation PLC and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Amarin Corporation PLC||$130.08 million||-$86.35 million||-12.33|
|Amarin Corporation PLC Competitors||$286.20 million||$34.74 million||146.61|
Amarin Corporation PLC’s peers have higher revenue and earnings than Amarin Corporation PLC. Amarin Corporation PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Amarin Corporation PLC and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Amarin Corporation PLC||-43.90%||N/A||-35.67%|
|Amarin Corporation PLC Competitors||-5,339.09%||-435.51%||-40.49%|
About Amarin Corporation PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.